Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of HRS-5041 combinations in advanced prostate cancer
CTR20243197Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5041 in prostate adenocarcinoma, sponsored by Hengrui Therapeutics. Started Sep 2024; status: active.
02
Drugs
HRS-5041
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20243197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243197.